// App-Quantinova.ai

1015 : Predictors of Nail Response with Guselkumab: A Post Hoc Analysis of the VOYAGE 2 Clinical Trial

Researchers

Presenter

  • Alexander Egeberg

Principal Investigators

  • William Tillett

  • Enikö Sonkoly

  • Patricia Gorecki

  • Anna Tjärnlund

  • Jozefien Buyze

  • Sven Wegner

  • Dennis McGonagle

Medical Centers

  • Department of Cardiology, Bispebjerg Hospital, Copenhagen, Denmark

  • Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

  • Dermatology and Venereology Division, Karolinska Institutet; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden

  • Janssen Cilag, High Wycombe, United Kingdom

  • , Janssen-Cilag, Solna, Sweden

  • Janssen Pharmaceutica NV, Beerse, Belgium

  • Janssen-Cilag GmbH, Neuss, Germany

  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

Locations

  • Denmark

  • United Kingdom

  • Sweden

  • Belgium

  • Germany

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved